{"disease":{"id":"maintenance-of-clinical-response-and-endoscopic-remission-in-adults-with-moderately-to-severely-active-ulcerative-colitis","name":"Maintenance of clinical response and endoscopic remission in adults with moderately to severely active ulcerative colitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"etrasimod","indication_name":"Maintenance of clinical response and endoscopic remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"etrasimod","guideline_body":"FDA label","recommendation":"VELSIPITY is indicated for the maintenance of clinical response and endoscopic remission in adults with moderately to severely active ulcerative colitis.","line_of_therapy":"maintenance","evidence_grade":"not specified","guideline_year":null},{"drug_id":"etrasimod","guideline_body":"FDA label","recommendation":"VELSIPITY is indicated for the maintenance of clinical response and endoscopic remission in adults with moderately to severely active Crohn's disease.","line_of_therapy":"maintenance","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}